BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, Li B, Dong PL, Li L, Ding HG. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol 2014; 20(32): 11400-11405 [PMID: 25170228 DOI: 10.3748/wjg.v20.i32.11400]
URL: https://www.wjgnet.com/1948-5182/full/v20/i32/11400.htm
Number Citing Articles
1
Ai Nakagawa, Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Tomomi Okubo, Taeang Arai, Norio Itokawa, Yoshiyuki Narahara, Katsuhiko Iwakiri. Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patientsWorld Journal of Gastroenterology 2016; 22(21): 5104-5113 doi: 10.3748/wjg.v22.i21.5104
2
Yu-hong Liu, Xiao-bo Han, Yue-hai Fei, Hong-tao Xu. Long-term low-dose tolvaptan treatment in hospitalized male patients aged >90 years with hyponatremiaMedicine 2017; 96(52): e9539 doi: 10.1097/MD.0000000000009539
3
Yoshitaka Arase, Tatehiro Kagawa, Kota Tsuruya, Hirohiko Sato, Erika Teramura, Kazuya Anzai, Shunji Hirose, Ryuzo Deguchi, Koichi Shiraishi, Tetsuya Mine. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory AscitesClinical Drug Investigation 2019; 39(1): 45 doi: 10.1007/s40261-018-0714-5
4
M.J. Broch Porcar, B. Rodríguez Cubillo, J.M. Domínguez-Roldán, L. Álvarez Rocha, M.Á. Ballesteros Sanz, M. Cervera Montes, M. Chico Fernández, J.H. de Gea García, P. Enríquez Giraudo, A. García de Lorenzo y Mateos, R. Gómez López, R. Guerrero Pavón, F. López Sánchez, J.A. Llompart-Pou, S. Lubillo Montenegro, Z. Molina Collado, P. Ramírez Galleymore, M. Riveiro Vilaboa, A. Sánchez Corral, M.E. Herrera-Gutiérrez. Practical document on the management of hyponatremia in critically ill patientsMedicina Intensiva (English Edition) 2019; 43(5): 302 doi: 10.1016/j.medine.2019.05.005
5
Makoto Segawa, Isao Sakaida. Clinical Investigation of Portal Hypertension2019; : 501 doi: 10.1007/978-981-10-7425-7_51
6
Ramesh Kumar, Rajeev Nayan Priyadarshi, Utpal Anand. Chronic renal dysfunction in cirrhosis: A new frontier in hepatologyWorld Journal of Gastroenterology 2021; 27(11): 990-1005 doi: 10.3748/wjg.v27.i11.990
7
Amruta Tripathy, Rituparna Maiti, Monalisa Jena, Archana Mishra, Anand Srinivasan. Effect of alpha agonists on the prevention of postparacentesis circulatory dysfunction in patients with refractory or recurrent ascites: a meta-analysisEuropean Journal of Gastroenterology & Hepatology 2020; 32(3): 303 doi: 10.1097/MEG.0000000000001594
8
Brett Fortune, Andres Cardenas. Ascites, refractory ascites and hyponatremia in cirrhosisGastroenterology Report 2017; 5(2): 104 doi: 10.1093/gastro/gox010
9
Salvatore Piano, Marta Tonon, Paolo Angeli. Evidence-based Gastroenterology and Hepatology 4e2019; : 662 doi: 10.1002/9781119211419.ch43
10
Y Suzuki, A Naganuma, T Hoshino, T Hatanaka, T Ueno, M Namikawa, D Takizawa, H Arai, H Suzuki, H Takagi, H Tojima, Y Yamazaki, K Sato, S Kakizaki, T Uraoka. Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort studyActa Gastro Enterologica Belgica 2021; 84(1): 57 doi: 10.51821/84.1.357
11
Haruki Uojima, Takeshi Kinbara, Hisashi Hidaka, Ji Hyun Sung, Masachika Ichida, Shinnosuke Tokoro, Sakue Masuda, Satoshi Takizawa, Akiko Sasaki, Kazuya Koizumi, Hideto Egashira, Makoto Kako. Close correlation between urinary sodium excretion and response to tolvaptan in liver cirrhosis patients with ascitesHepatology Research 2017; 47(3): E14 doi: 10.1111/hepr.12716
12
Nitish Rai, Baljinder Singh, Akash Singh, Rajesh Vijayvergiya, Navneet Sharma, Ashish Bhalla, Virendra Singh. Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot studyLiver International 2017; 37(3): 406 doi: 10.1111/liv.13250
13
Hiroshi Fukui. Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites?World Journal of Gastroenterology 2015; 21(41): 11584-11596 doi: 10.3748/wjg.v21.i41.11584
14
P. Angeli. The first Chinese guidelines on the Management of Ascites and its Related Complications in Cirrhosis: a great goal for a great countryHepatology International 2019; 13(4): 395 doi: 10.1007/s12072-019-09961-4
15
Hiroyuki Nakanishi, Masayuki Kurosaki, Takanori Hosokawa, Yuka Takahashi, Jun Itakura, Shoko Suzuki, Yutaka Yasui, Nobuharu Tamaki, Natsuko Nakakuki, Hitomi Takada, Mayu Higuchi, Yasuyuki Komiyama, Tsubasa Yoshida, Kenta Takaura, Tsuguru Hayashi, Konomi Kuwabara, Sei Sasaki, Namiki Izumi. Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascitesJournal of Gastroenterology 2016; 51(6): 620 doi: 10.1007/s00535-015-1143-3
16
M.J. Broch Porcar, B. Rodríguez Cubillo, J.M. Domínguez-Roldán, L. Álvarez Rocha, M.Á. Ballesteros Sanz, M. Cervera Montes, M. Chico Fernández, J.H. de Gea García, P. Enríquez Giraudo, A. García de Lorenzo y Mateos, R. Gómez López, R. Guerrero Pavón, F. López Sánchez, J.A. Llompart-Pou, S. Lubillo Montenegro, Z. Molina Collado, P. Ramírez Galleymore, M. Riveiro Vilaboa, A. Sánchez Corral, M.E. Herrera-Gutiérrez. Documento práctico del manejo de la hiponatremia en pacientes críticosMedicina Intensiva 2019; 43(5): 302 doi: 10.1016/j.medin.2018.12.002
17
Dmitry Victorovich Garbuzenko, Nikolay Olegovich Arefyev. Current approaches to the management of patients with cirrhotic ascitesWorld Journal of Gastroenterology 2019; 25(28): 3738-3752 doi: 10.3748/wjg.v25.i28.3738
18
Shuzhen Wang, Xin Zhang, Tao Han, Wen Xie, Yonggang Li, Hong Ma, Roman Liebe, Honglei Weng, Hui-Guo Ding. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremiaBMC Gastroenterology 2018; 18(1) doi: 10.1186/s12876-018-0857-0
19
Takamasa Ohki, Koki Sato, Tomoharu Yamada, Mari Yamagami, Daisaku Ito, Koki Kawanishi, Kentaro Kojima, Michiharu Seki, Nobuo Toda, Kazumi Tagawa. Efficacy of tolvaptan in patients with refractory ascites in a clinical settingWorld Journal of Hepatology 2015; 7(12): 1685-1693 doi: 10.4254/wjh.v7.i12.1685
20
HISAMITSU MIYAAKI, YUTAKA NAKAMURA, TATSUKI ICHIKAWA, NAOTA TAURA, SATOSHI MIUMA, HIDETAKA SHIBATA, TAKUYA HONDA, KAZUHIKO NAKAO. Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearanceBiomedical Reports 2015; 3(6): 884 doi: 10.3892/br.2015.521
21
Satoru Hagiwara, Naoshi Nishida, Hirokazu Chishina, Hiroshi Ida, Toshiharu Sakurai, Yoriaki Komeda, Masayuki Kitano, Masatoshi Kudo. Cases with Refractory Ascites and a Delayed Response to TolvaptanInternal Medicine 2016; 55(22): 3273 doi: 10.2169/internalmedicine.55.7035
22
Yasunari Hiramine, Haruki Uojima, Hiroyuki Nakanishi, Akira Hiramatsu, Takuya Iwamoto, Mutsuumi Kimura, Hideto Kawaratani, Shuji Terai, Hitoshi Yoshiji, Hirofumi Uto, Isao Sakaida, Namiki Izumi, Kiwamu Okita, Kazuhiko Koike. Response criteria of tolvaptan for the treatment of hepatic edemaJournal of Gastroenterology 2018; 53(2): 258 doi: 10.1007/s00535-017-1366-6
23
Kazuto Tajiri, Yoshiharu Tokimitsu, Hiroyuki Ito, Yoshinari Atarashi, Kengo Kawai, Masami Minemura, Satoshi Yasumura, Terumi Takahara, Yukihiro Shimizu, Toshiro Sugiyama. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced CirrhosisDigestive Diseases 2018; 36(4): 314 doi: 10.1159/000489258
24
Patricia Huelin, Jose Ignacio Fortea, Javier Crespo, Emilio Fábrega. Ascites - Physiopathology, Treatment, Complications and Prognosis2017;  doi: 10.5772/intechopen.70384